Targeted Disruption of Heparan Sulfate Interaction with Hepatocyte and Vascular Endothelial Growth Factors Blocks Normal and Oncogenic Signaling

SummaryHepatocyte growth factor (HGF) and vascular endothelial cell growth factor (VEGF) regulate normal development and homeostasis and drive disease progression in many forms of cancer. Both proteins signal by binding to receptor tyrosine kinases and heparan sulfate (HS) proteoglycans on target cell surfaces. Basic residues comprising the primary HS binding sites on HGF and VEGF provide similar surface charge distributions without underlying structural similarity. Combining three acidic amino acid substitutions in these sites in the HGF isoform NK1 or the VEGF isoform VEGF165 transformed each into potent, selective competitive antagonists of their respective normal and oncogenic signaling pathways. Our findings illustrate the importance of HS in growth factor driven cancer progression and reveal an efficient strategy for therapeutic antagonist development.

Graphical AbstractFigure optionsDownload high-quality image (317 K)Download as PowerPoint slideHighlights
► Heparan sulfate glycosaminoglycans (HS) are critical growth factor coreceptors
► Growth factors and HS regulate development, homeostasis, and cancer progression
► HS polymers cluster growth factors to aid receptor activation
► Disrupting growth factor-HS binding blocks signaling and cancer progression